Intech Biopharm Corporation

6461

TW0006461007

Pharmaceuticals

End-of-day quote Taipei Exchange Other stock markets 23:00:00 28/05/2024 BST			5-day change	1st Jan Change
27.2 ^TWD	+0.74%		+0.74%	-9.03%

03-13	Intech Biopharm Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Intech Biopharm Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Intech Biopharm Corporation announced that it expects to receive TWD 350 million in funding

December 27, 2017

Intech Biopharm Corporation (GTSM:6461) announced a private placement of 10,000,000 shares at a price of TWD 35 per share for gross proceeds of TWD 350 million on Decemebr 28, 2017.

Latest news about Intech Biopharm Corporation

Intech Biopharm Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	03-13	CI
Intech Biopharm Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-10	CI
Intech Biopharm Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	08/08/23	CI
Intech Biopharm Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	12/05/23	CI
Intech Biopharm Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	29/03/23	CI
Intech Biopharm Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	09/11/22	CI
Intech Biopharm Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	10/08/22	CI
Intech Biopharm Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022	11/05/22	CI
Intech Biopharm Corporation Reports Earnings Results for the Full Year Ended December 31, 2021	28/03/22	CI
Intech Biopharm Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	11/11/21	CI
Intech Biopharm Corporation Reports Earnings Results for the Second Quarter Ended June 30, 2021	13/08/21	CI
Intech Biopharm Corporation Reports Earnings Results for the First Quarter Ended March 31, 2021	13/05/21	CI
Intech Biopharm Corporation Reports Earnings Results for the Full Year Ended December 31, 2020	24/03/21	CI
Intech Biopharm Corporation Reports Earnings Results for the Third Quarter Ended September 30, 2020	11/11/20	CI
Intech Biopharm Corporation Reports Earnings Results for the Second Quarter Ended June 30, 2020	12/08/20	CI
Intech Biopharm Corporation Reports Earnings Results for the First Quarter Ended March 31, 2020	13/05/20	CI
Intech Biopharm Corporation Reports Earnings Results for the Full Year Ended December 31, 2019	30/03/20	CI
Intech Biopharm Corporation Reports Earnings Results for the Third Quarter Ended September 30, 2019	12/11/19	CI
Intech Biopharm Corporation Reports Earnings Results for the Second Quarter Ended June 30, 2019	12/08/19	CI
Intech Biopharm Corporation Reports Earnings Results for the First Quarter Ended March 31, 2019	13/05/19	CI
Intech Biopharm Corporation Reports Earnings Results for the Full Year Ended December 31, 2018	26/03/19	CI
Intech Biopharm Corporation announced that it has received TWD 352.3 million in funding	25/03/18	CI
Intech Biopharm Corporation announced that it expects to receive TWD 350 million in funding	27/12/17	CI

Chart Intech Biopharm Corporation

Duration

Period

More charts

INTECH BIOPHARM LTD. is a Taiwan-based company principally engaged in the research, development, manufacture and sales of inhalants and related products. The Company's main products include respiratory drugs, the Duasma hexafluoroacetone (HFA) metered-dose inhalers (MDIs) and the Synvent HFA MDIs. The Company distributes its products in domestic market and to overseas markets.

Sector

Pharmaceuticals

Calendar

06/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
INTECH BIOPHARM CORPORATION	-9.03%	115M
MERCK KGAA	+15.06%	79.23B
KYOWA KIRIN CO. LTD.	+8.92%	8.66B
SK BIOPHARMACEUTICALS CO., LTD.	-17.73%	4.72B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+56.03%	4.89B
YUHAN CORPORATION	+1.31%	3.81B
INDIVIOR PLC	+20.51%	2.42B
BETTA PHARMACEUTICALS CO., LTD.	-25.43%	2.22B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+14.61%	2.08B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-37.31%	1.96B